AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

AstraZeneca Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a ...

If we don’t incentivize continued investments in drug research and development, we’ll lose out on new therapies that don’t ...

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...

Prescription drugs account for 15% of health care costs. Yet, they’re our best defense against the chronic diseases that ...

President Donald Trump’s “big, beautiful bill,” which he signed into law earlier this month, includes major wins for business ...

Drug development is a decade-long, costly process replete with failures. If we don’t incentivize investments in research and ...